Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $825.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 37.7% year-over-year to $825.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (up 30.07% YoY), and the FY2025 full-year result was $763.6 million, up 31.54% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $825.3 million, up from $763.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $825.3 million in Q1 2026, with the low at $210.6 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $532.8 million across 5 years, with a median of $526.3 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 25.77% — and 2023, when it jumped 130.0%.
• Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity stood at $459.7 million in 2022, then gained by 14.5% to $526.3 million in 2023, then advanced by 10.3% to $580.6 million in 2024, then surged by 31.54% to $763.6 million in 2025, then climbed by 8.07% to $825.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $825.3 million (Q1 2026), $763.6 million (Q4 2025), and $712.3 million (Q3 2025), per Business Quant data.